Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16464206 | 0.80 | P2RX7 (0.38) | KCNA5ALDH1A1KDM4EHSD17B10KCNH2 | |
| SCHEMBL5114145 | 0.80 | ALDH1A1 (0.44) | KCNA5ALDH1A1KDM4ECYP3A4CYP2C19 | |
| SCHEMBL1240803 | 0.79 | KCNA5 (0.52) | KCNA5ALDH1A1KDM4EHSD17B10KCNH2 | |
| SCHEMBL855649 | 0.79 | KCNA5 (0.53) | KCNA5ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5000351 | 0.79 | KCNA5 (0.53) | KCNA5ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5027031 | 0.77 | KCNA5 (0.50) | KCNA5ALDH1A1KDM4EHSD17B10KCNH2 | |
| SCHEMBL22639946 | 0.77 | ALDH1A1 (0.59) | ALDH1A1KDM4EHSD17B10CYP3A4CYP2C9 | |
| SCHEMBL22958209 | 0.77 | ALDH1A1 (0.62) | KCNA5ALDH1A1KDM4EHSD17B10CYP3A4 | |
| SCHEMBL9363512 | 0.77 | ALDH1A1 (0.56) | KCNA5ALDH1A1SMN1; SMN2 | |
| SCHEMBL2570964 | 0.77 | ALDH1A1 (0.59) | ALDH1A1KDM4EHSD17B10CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| US-20100298328-A1 | 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes | VITAE PHARMACEUTICALS, INC | 2010-11-25 | — | — | US | claimed |
| WO-2007123718-A1 | 1-HETEROCYCLYLAMINO-2-HYDROXY-3-AMINO-ω-ARYLALKANES | VITAE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | WO | claimed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| CN-109970708-B | Cannabinoid receptor modulators | 艾尼纳制药公司 | 2022-06-21 | — | — | CN | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2005082340-A2 | MODULATION OF INFLAMMATORY AND METASTATIC PROCESSES | CHIRON CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050137399-A1 | A lithium-free reaction to produce a substituted/unsubstituted 4-amino-3-benzimidazol-2-yl-quinolin-2-one compound by reacting a 2-aminobenzonitrile with a 2-alkyloxycarbonylmethyl-benzimidazole in a solvent in the presence of a sodium or potassium salt of a base; excellent yields | CHIRON CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005046590-A2 | METHODS FOR SYNTHESIZING QUINOLINONE COMPOUNDS | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | KCNA5 704/4885ALDH1A1 3623/4885KDM4E 3533/4885 |
| US-20100298328-A1 | 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes | REN, AGTR1, AGTR2 | KCNA5 878/4885ALDH1A1 189/4885KDM4E 3554/4885 |
| US-20050137399-A1 | A lithium-free reaction to produce a substituted/unsubstituted 4-amino-3-benzimidazol-2-yl-quinolin-2-one compound by reacting a 2-aminobenzonitrile with a 2-alkyloxycarbonylmethyl-benzimidazole in a solvent in the presence of a sodium or potassium salt of a base; excellent yields | KCNJ2, KCNN2, KCNN1 | KCNA5 38/4885ALDH1A1 2263/4885KDM4E 691/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | KCNA5 4078/4885ALDH1A1 152/4885KDM4E 2562/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | KCNA5 704/4885ALDH1A1 3623/4885KDM4E 3533/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | KCNA5 704/4885ALDH1A1 3623/4885KDM4E 3533/4885 |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | KCNA5 874/4885ALDH1A1 2692/4885KDM4E 3391/4885 |
| US-20210188781-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | KCNA5 704/4885ALDH1A1 3623/4885KDM4E 3533/4885 |
| US-11771695-B2 | Cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | KCNA5 874/4885ALDH1A1 2692/4885KDM4E 3391/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | KCNA5 704/4885ALDH1A1 3623/4885KDM4E 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.